Low expression of BCL2L12 is associated with poor prognosis in cytogenetically normal acute myeloid leukemia patients
作者单位：Institute of HematologyZhejiang University School of Medicine
会议名称：《2014浙江省医学会血液病学学术年会》
会议日期：2014年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
关 键 词：BCL2L12 cytogenetically normal acute myeloid leukemia prognosis
摘 要：BCL2L12,a member of BCL2 family,is closely associated with *** literature revealed that BCL2L12 expression level predicted the prognosis of some cancers,such as breast cancer and gastrointestinal ***,its role in cytogenetically normal acute myeloid leukemia(CN-AML) remains *** this study,BCL2L12 expression level was measured in 107 CN-AML patients and 49 healthy donors by real-time polymerase chain reaction and its prognostic value was *** results showed that,compared with healthy donors,CN-AML patients harbored a significant lower BCL2L12 gene expression(P=0.001).Expression level of BCL2L12 was not associated with age,sex,white blood count,hemoglobin,platelet,CEBPA mutations,DNMT3 A mutations,IDH1 mutations and IDH2 ***,lower expression level of BCL2L12 was more frequently found in CN-AML patients with FLT3-ITD and without NPMl mutations(P=0.045).Kaplan-Meier survival analysis demonstrated that patients with low BCL2L12 expression level had a significant shorter overall survival(P=0.025) and event free survival(P=0.042).Multivariate analysis revealed that BCL2L12 expression was an independent prognostic factor for CN-AML *** data indicate that BCL2L12 gene expression be a potential and useful biomarker for predicting prognosis and risk stratification in CN-AML patients.